KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.51 | -1.00 | 2.98 | -0.09 |
| FCF Yield | -22.43% | -21.48% | -30.91% | -25.38% |
| EV / EBITDA | -3.41 | -2.93 | -2.11 | -3.58 |
| Quality | ||||
| ROIC | -90.57% | -61.55% | -65.50% | -49.99% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.83 | 0.70 | 0.81 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -71.00% | -17.29% | 3.30% | -161.35% |
| Safety | ||||
| Net Debt / EBITDA | 0.53 | 0.18 | 0.51 | 0.28 |
| Interest Coverage | -32.50 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -38.58 | 0.00 | 0.00 |